REG - Theracryf PLC - Director/PDMR Shareholding

TheracryfAnnouncement

16/10/2025 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251016:nRSP7272Da&default-theme=true

RNS Number : 7272D  Theracryf PLC  16 October 2025

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Share Purchase by a Director

Alderley Park, UK - 16 October 2025: TheraCryf plc (AIM: TCF), the clinical
stage drug development company focussing on brain disorders, announces that
Northern Standard Limited, a company that Non-Executive Director, Ed Wardle,
has a 49 per cent interest in purchased 7,342,296 ordinary shares of 0.25
pence each in the Company ("Ordinary Shares") on 14 October 2025 at a price of
£0.00175 and now owns 430,069,568 Ordinary Shares.

As a result, Mr Wardle is deemed to have an interest in 430,069,568 Ordinary
Shares, representing 20.01 per cent of the Company's issued Ordinary Shares.

Enquiries

 TheraCryf plc                                       +44 (0)1625 315 090

 Dr Huw Jones, CEO                                   enquiries@theracryf.com

 Toni Hänninen, CFO

 Dr Helen Kuhlman, COO

 Singer Capital Markets (NOMAD & Joint Broker)       +44 (0)20 7496 3000
 Phil Davies / Oliver Platts / Patrick Weaver

 Turner Pope Investments (Joint Broker)              +44 (0)20 3657 0050

 James Pope / Andy Thacker

 Vigo Consulting                                     +44 (0)20 7390 0230

 Rozi Morris/ Melanie Toyne Sewell                   theracryf@vigoconsulting.com

About TheraCryf plc

TheraCryf is the clinical stage drug development company focussing on brain
disorders. The Company has a broad clinical and preclinical pipeline in
indications including addiction, anxiety, fatigue, narcolepsy, glioblastoma*
and neurodevelopmental disorders [*orphan indication].

 

The Company's strategy is to generate compelling data sets to preclinical
and/or clinical proof of concept and partner its clinical programmes with
mid-size to large pharma for larger trials and commercialisation. It also has
a number of industry partnerships with companies, including Stalicla SA, in
neurodevelopmental disorders.  The Company has sourced know-how for
programmes from companies such as Shire (now Takeda).

 

TheraCryf has worked with and has ongoing collaborations with major
universities and hospitals such as the University of Manchester, La Sapienza
(Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College
London and the University of Michigan.

 

The Company has its headquarters and registered office at Alderley
Park, Cheshire. It is quoted on AIM in London and trades under the
ticker symbol TCF. 

 1.  Details of PDMR / person closely associated with them ("PCA")
 a)  Name                                     Edward James Norman Wardle
 b)  Position / status                        Non Executive Director
 c)  Initial notification / amendment         Initial notification
 2.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument  Theracryc PLC
 b)  Nature of the transaction                Acquisition of ordinary shares by Northern Standard Limited, a company that
                                              Edward James Norman Wardle has 49% ownership of
 c)  Price(s) and volume(s)                   Price(s)   Volume(s)
                                              £0.00175   7,342,296

 

 d)  Aggregated information                   See above

     -    Aggregated volume

     -    Price
 e)  Date of the transaction                  14 October 2025
 f)  Place of the transaction                 Outside a trading venue

 

 

d)

Aggregated information

-    Aggregated volume

-    Price

See above

e)

Date of the transaction

14 October 2025

f)

Place of the transaction

Outside a trading venue

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEASEKFDFSFFA



            Copyright 2019 Regulatory News Service, all rights reserved